NUC-1031

DRUG2 trials

Sponsors

Imperial College London, NuCana plc

Conditions

Biliary Tract CancerCancer

Phase 1

NUC-1031 in Patients With Advanced Solid Tumours

CompletedNCT01621854

Imperial College LondonCancer

Start: 2012-10-31End: 2015-06-30Updated: 2024-03-20

Phase 3

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

TerminatedNCT04163900

NuCana plcBiliary Tract Cancer

Start: 2019-12-24End: 2022-04-05Updated: 2023-05-24

Related Papers

A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.

2025-02-183 citations

Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Journal of Clinical Oncology2021-05-201 citations

Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Journal of Clinical Oncology2021-01-204 citations

NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)

Future Oncology2020-05-0617 citations

NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Journal of Clinical Oncology2020-02-012 citations

Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.

Journal of Clinical Oncology2015-05-207 citations

A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers.

Journal of Clinical Oncology2015-05-205 citations

ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-201 citations